Loading patent…
AssigneeSylentis S.A.U.
InventorsAna Isabel JIMENEZ, Covadonga PAÑEDA, Tamara MARTINEZ
Estimating the term…
The invention relates to siRNA molecules and their use in methods and pharmaceutical compositions for inhibiting the expression of the PDK1 gene. The invention also relates to the use of said siRNAs molecules in the treatment and/or prevention of an eye condition characterised by increased expression and/or activity of PDK1 gene, preferably said eye condition is conjunctivitis and/or an ocular allergy such as seasonal allergic conjunctivitis, perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, and giant papillary conjunctivitis.
An siRNA molecule wherein said molecule specifically targets at least one sequence selected from the group consisting of SEQ ID NO. 1-SEQ ID NO. 687, for use as a medicament.
An siRNA molecule according to any preceding claim wherein said siRNA comprises a 19 nucleotide double-stranded region.
An siRNA molecule according to any preceding claim wherein said siRNA comprises or consists of at least one sequence selected from the group consisting of SEQ ID NO. 688-SEQ ID NO. 1374.
An siRNA molecule wherein said molecule specifically targets at least one sequence selected from the group consisting of SEQ ID NO. 1-SEQ ID NO. 687 and reduces expression of PDK1 gene when introduced in a cell and wherein said siRNA comprises a 19 nucleotide blunt-ended double-stranded structure.
An siRNA molecule according to any preceding claim, wherein at least one nucleotide comprises a chemical modification.
Use of an siRNA molecule according to any preceding claim in the manufacture of a medicament for the treatment of an eye condition characterised by increased expression and/or activity of PDK1.
Dependencies are inferred from the claim text.